Vomiting News and Research RSS Feed - Vomiting News and Research

Vomiting is the process the body uses to eject some or all of the contents of the stomach through the mouth.
Statement on Ebola epidemic

Statement on Ebola epidemic

The Ebola virus is spreading rapidly and to an unexpected extent. The outbreak does not follow the patterns experienced in the past and the virus shows a new disease dynamic in regions, where it has never been recorded before. For this reason, the German National Academy of Sciences Leopoldina, acatech – the German Academy of Science and Engineering, and the Union of the German Academies of Sciences and Humanities have presented a statement on the Ebola epidemic today. [More]
Second Dallas health worker has Ebola; CDC announces 'more robust' response

Second Dallas health worker has Ebola; CDC announces 'more robust' response

Seventy-six health-care workers who helped treat Ebola patient Thomas Eric Duncan are now being monitored for potential Ebola exposure. Forty-eight others are being watched because they had contact with Duncan. [More]
Boehringer Ingelheim's OFEV (nintedanib) capsules receive FDA approval for IPF treatment

Boehringer Ingelheim's OFEV (nintedanib) capsules receive FDA approval for IPF treatment

Boehringer Ingelheim Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration approved OFEV (nintedanib) capsules for oral use for the treatment of idiopathic pulmonary fibrosis (IPF). [More]
Most surgical patients lack knowledge about roles of physician anesthesiologists

Most surgical patients lack knowledge about roles of physician anesthesiologists

Most surgical patients know a physician anesthesiologist will "put them to sleep," but what they don't realize is that this medical doctor plays a major role in preparing them for the operation. Just as important, these physicians keep them safe and preserve their health during surgery and help them recover as quickly and as comfortably as possible, according to a study presented at the ANESTHESIOLOGY 2014 annual meeting. [More]
Eisai, Helsinn Group announce FDA approval of AKYNZEO for prevention of CINV

Eisai, Helsinn Group announce FDA approval of AKYNZEO for prevention of CINV

Helsinn Group and Eisai Inc. announced today that the Food and Drug Administration (FDA) approved AKYNZEO® for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of cancer chemotherapy, including, but not limited to, highly emetogenic chemotherapy. [More]
Texas health worker contracts Ebola, fueling questions about training and preparedness

Texas health worker contracts Ebola, fueling questions about training and preparedness

The case, the first in which the disease was transmitted in the U.S., raises questions about whether regular hospitals around the country are ready to safely deal with the virus. [More]
Web-based system could help improve detection of disease outbreaks, say researchers

Web-based system could help improve detection of disease outbreaks, say researchers

A web-based system that allows preschools and child care centers to report illnesses to local public health departments could improve the detection of disease outbreaks and allow resources to be mobilized more quickly, according to University of Michigan research to be presented Saturday, Oct. 11 at the American Academy of Pediatrics (AAP) National Conference & Exhibition in San Diego. [More]
Quick, forceful implementation of control interventions necessary to control Ebola outbreaks

Quick, forceful implementation of control interventions necessary to control Ebola outbreaks

New Ebola research demonstrates that quick and forceful implementation of control interventions are necessary to control outbreaks and avoid far worse scenarios. [More]
Views on giving flu shot to younger children

Views on giving flu shot to younger children

It's a common question parents ask themselves this time of year: Does my child really need a flu shot? Though the flu may seem harmless, the truth is on average 20,000 children age 5 and younger are hospitalized due to flu symptoms each year. [More]
CHOP joins CEGIR to advance treatment of eosinophilic disorders

CHOP joins CEGIR to advance treatment of eosinophilic disorders

The Children's Hospital of Philadelphia has joined a new consortium announced today by the National Institutes of Health to advance the treatment of chronic inflammatory diseases called eosinophilic disorders. [More]
Pediatric specialist in EGIDs helps lead $6.25 million NIH clinical research project

Pediatric specialist in EGIDs helps lead $6.25 million NIH clinical research project

A pediatric specialist in eosinophilic gastrointestinal diseases (EGIDs) at the University of Colorado School of Medicine and Children's Hospital Colorado will help lead a five-year, $6.25 million clinical research project recently funded by the National Institutes of Health. [More]
Isavuconazole demonstrates successful outcomes in treatment of mucormycosis

Isavuconazole demonstrates successful outcomes in treatment of mucormycosis

Astellas reported today that isavuconazole demonstrated successful outcomes in the treatment of mucormycosis according to data from the phase 3 isavuconazole VITAL study being presented at IDWeek on October 10, 2014, in Philadelphia, Pa. [More]
Ferring Pharmaceuticals to introduce new cranberry flavor option of PREPOPIK in 2015

Ferring Pharmaceuticals to introduce new cranberry flavor option of PREPOPIK in 2015

Colonoscopy is an important and widely used screening tool for colorectal cancer, but for many patients the bowel-preparation process is more uncomfortable than the procedure itself. To offer an alternative choice in bowel preparation, Ferring Pharmaceuticals Inc. will introduce a new cranberry flavor option of PREPOPIK in January 2015. [More]
Acacia Pharma reports positive results from APD421 Phase 3 studies for management of PONV

Acacia Pharma reports positive results from APD421 Phase 3 studies for management of PONV

Acacia Pharma announces positive Phase 3 results with APD421 for the management of post-operative nausea & vomiting (PONV). The data generated demonstrated a statistically significant reduction in the incidence of PONV with APD421 compared to placebo in adult surgical patients at moderate to high risk of suffering PONV (PONV is defined as any episode of emesis or use of antiemetic rescue medication in the first 24 hours after surgery). [More]

Correcting flaws in the Ebola response

How hospital and health workers react to suspected cases of Ebola going forward is the subject of much scrutiny. But, even as public health and many elected officials urge calm, some potential 2016 presidential candidates say President Obama isn't doing enough to keep the disease out of the U.S. [More]
UPM researchers find way to enhance detection of rotavirus

UPM researchers find way to enhance detection of rotavirus

Researchers at the Universidad Politécnica de Madrid have found a way to enhance detection capacity of small concentrations of rotavirus. All this thanks to a new way to assess the biosensing response applied to an interferometric device. [More]
Family physician  answers questions related to Ebola virus

Family physician answers questions related to Ebola virus

According to the Centers for Disease Control, the outbreak of Ebola in four West African countries is one of the largest outbreaks of the disease in history. [More]
Rapid and coordinated response helps control Ebola outbreak in Nigeria

Rapid and coordinated response helps control Ebola outbreak in Nigeria

The Ebola outbreak in Nigeria appears to be nearing a possible end thanks to a rapid response coordinated by Nigeria's Emergency Operations Center with assistance from international partners, including the U.S. Centers for Disease Control and Prevention (CDC). [More]
Luminex gets FDA approval to add three new targets to xTAG Gastrointestinal Pathogen Panel

Luminex gets FDA approval to add three new targets to xTAG Gastrointestinal Pathogen Panel

Luminex Corporation today announced it has received U.S. FDA clearance to add three new targets to its xTAG Gastrointestinal Pathogen Panel (GPP). The targets include Adenovirus 40/41, Entamoeba histolytica and Vibrio cholerae. [More]
Phase 3 COU-AA-302 results show ZYTIGA plus prednisone prolongs overall survival in men with chemotherapy-naive mCRPC

Phase 3 COU-AA-302 results show ZYTIGA plus prednisone prolongs overall survival in men with chemotherapy-naive mCRPC

A final analysis of the Phase 3 COU-AA-302 trial presented today at the European Society for Medical Oncology (ESMO) 2014 Congress in Madrid, Spain showed that ZYTIGA® (abiraterone acetate) plus prednisone significantly prolonged overall survival (OS), compared to an active control of placebo plus prednisone, in men with chemotherapy-naive metastatic castration-resistant prostate cancer (mCRPC). [More]